Silence Therapeutics PLC

OTC:SLNCF

Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. The firm is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a), or Lp(a), levels and SLN124, for rare iron loading anemia conditions, including thalassemia and myelodysplastic syndrome (MDS).